Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency

Anna M. Johansson; Andreas Hillarp; Torbjörn Säll; Bengt Zöller; Björn Dahlbäck; Christer Halldén

doi:10.1160/TH05-06-0392

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2005; 94(05): 951-957
DOI: 10.1160/TH05-06-0392

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency

Anna M. Johansson

¹Department of Cell and Organism Biology, Lund University, Lund, Sweden

,

Andreas Hillarp

¹Department of Cell and Organism Biology, Lund University, Lund, Sweden

,

Torbjörn Säll

¹Department of Cell and Organism Biology, Lund University, Lund, Sweden

,

Bengt Zöller

¹Department of Cell and Organism Biology, Lund University, Lund, Sweden

,

Björn Dahlbäck

¹Department of Cell and Organism Biology, Lund University, Lund, Sweden

,

Christer Halldén

²Department of Clinical Chemistry, University Hospital, Malmö, Sweden

› Institutsangaben

Abstract

Summary

Protein S deficiency is an autosomal dominant disorder that results from mutations in the PROS1 gene. Conventional mutation detection techniques fail to detect a pathogenic PROS1 mutation in approximately 50% of cases. The present study investigates whether large deletions of PROS1 are found in families where mutations in the PROS1 gene have not been found despite sequencing. For this purpose, a dense set of SNP and microsatellite markers were used in segregation analysis to identify deletions. Large deletions were identified by this technique in three out of eight investigated families (38%). The deletions encompassed at least 35 kb, 437 kb and 449 kb respectively. The deletions were confirmed by quantitative PCR. Haplotype analysis showed that the three large deletions and the five other disease haplotypes were all different. All of the eight disease haplotypes co-segregated with protein S deficiency, but each of the five non-deletion haplotypes were present also in normal individuals. In conclusion: Large deletions of PROS1 are relatively common in protein S deficiency patients and screening for large deletions in PROS1 mutation-negative individuals are therefore warranted.

Keywords

Deletion - mutation - protein S deficiency - PROS1

Volltext

Referenzen

References
1 Lewis BE, Wallis DE, Leya F. et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-56.
2 Lewis BE, Matthai Jr WH, Cohen M. et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57: 177-84.
3 Greinacher A, Volpel H, Janssens U. et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
4 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103: 1479-84.
5 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
6 Eriksson BI, Agnelli G, Cohen AT. et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-96.
7 Gosselin RC, Dager WE, King JH. et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004; 121: 593-9.
8 Sheth SB, DiCicco RA, Hursting MJ. et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85: 435-40.
9 Harder S, Graff J, Klinkhardt U. et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 2004; 91: 1137-45.
10 Francis JL, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia [abstract]. Blood 2003; 102 (Suppl. 01) 164a.
11 Greinacher A, Eichler P, Lubenow N. et al. Heparininduced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
12 Kikumoto R, Tamao Y, Tezuka T. et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
13 Römisch J, Diehl KH, Hoffmann D. et al. Comparison of in vitro and in vivo properties of rHirudin (HBW 023) and a synthetic analogous peptide. Haemostasis 1993; 23: 249-58.
14 Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994; 33: 14807-14.
15 Ofosu FA, Fenton II JW, Maraganore J. et al. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. Biochem J 1992; 283: 893-7.
16 Ofosu FA. Mechanisms for the anticoagulant effects of synthetic antithrombins. Adv Exp Med Biol 1993; 340: 213-26.
17 Ofosu FA, Lormeau JC, Craven S. et al. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb Haemost 1994; 72: 862-8.
18 Dyke CK, Becker RC, Kleiman NS. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease. A pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
19 Tobu M, Iqbal O, Hoppensteadt D. et al. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thrombosis Hemostasis 2004; 10: 301-9.
20 Nar H, Bauer M, Schmid A. et al. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure 2001; 9: 29-37.
21 Gouin-Thibault I, Dewar L, Kulczycky M. et al. Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo. Br J Haematol 1995; 90: 669-80.
22 Ofosu FA, Fareed J, Smith LM. et al. Inhibition of factor X, factor V and prothrombin by the bis-lactobionic acid amide LW10082. Eur J Biochem 1992; 203: 121-5.
23 Pötzsch B, Hund S, Madlener K. et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86: 373-83.
24 Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 1980; 19: 1013-9.
25 Okwusidi JI, Anvari N, Ofosu FA. Modulation of intrinsic prothrombin activation by fibrinogen and fibrin I. J Lab Clin Med 1993; 121: 64-70.
26 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9.
27 Gustafsson D, Antonsson T, Bylund R. et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8.
28 Lewis BE, Hursting MJ. Argatroban therapy in heparin- induced thrombocytopenia. Warkentin TE, Greinacher A. Heparin-induced Thrombocytopenia. 3rd ed. New York: Marcel Dekker, Inc.; 2004: 437-74.
29 Mattsson C, Menschiek-Lundin A, Wahlander K. et al. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001; 86: 611-5.
30 Fareed J. New insights into the pharmacology of argatroban and potential clinical relevance. Thromb Haemost. 2004 Suppl 14-21.
31 Maraganore JM, Chao B, Joseph ML. et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8.
32 Warkentin TE, Hayward CPM, Boshkov LK. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
33 Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
34 Rydel TJ, Ravichandran KG, Tulinsky A. et al. The structure of a complex of recombinant human hirudin and human α-thrombin. Science 1990; 249: 277-80.
35 Grutter MG, Priestle JP, Rahuel J. et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5.
36 Stubbs MT, Bode W. The clot thickens: clues provided by thrombin structure. Trends Biochem Sci 1995; 20: 23-8.
37 Fischer BE, Schlokat U, Himmelspach M. et al. Binding of hirudin to meizothrombin. Protein Eng 1998; 11: 715-21.
38 Anderson PJ, Nesset A, Bock PE. Effects of activation peptide bond cleavage and fragment 2 interactions on the pathway of exosite I expression during activation of human prethrombin 1 to thrombin. J Biol Chem 2003; 278: 44482-8.